Martí-Cabrera M, Marti-Masanet M, Ríos-Navarro C, Polo PM, Esplugues MJV

Idioma: Español
Referencias bibliográficas: 52
Paginas: 431-444
Archivo PDF: 194.71 Kb.

RESUMEN

Antecedentes: La asociación entre los inhibidores de la bomba de protones (IBP) y el riesgo de osteoporosis y fracturas óseas es un tema que ha originado, recientemente, bastante interés en la literatura médica. Los IBP son los fármacos de primera elección en enfermedades que evolucionan con incremento de la secreción ácida y, debido al aumento progresivo de su prescripción, su potencial toxicidad se investiga periódicamente.
Objetivos: En la presente revisión se analizan las bases fisiofarmacológicas y la limitada evidencia clínica de una potencial relación entre la administración continuada de IBP y la aparición de osteoporosis y fracturas óseas. Ambas patologías, relacionadas con la homeostasis del calcio, son de gran importancia en pacientes de edad avanzada por su mal pronóstico general y las consecuencias invalidantes que conllevan.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Esplugues JV, Martí-Cabrera M, Ponce J. Seguridad de la utilización de los inhibidores de la bomba de protones. Med Clin (Barc). 2006;127: 790-5.

2. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903.

3. Esplugues JV, Marti-Cabrera M. Seguridad e interacciones de los inhibidores de la bomba de protones: lecciones aprendidas en millones de pacientes. Gastroenterol Hepatol. 2010;33(Supl 1):15-21.

4. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115-27.

5. Pharm CQ, Regal RE, Bostwick TR, et al. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacothe 2006;40: 1261-6.

6. Parker M, Johansen A. Hip fracture. BMJ. 2006;333:27-30.

7. Riggs BL, Melton III LJ. Involutional osteoporosis. N Engl J Med. 1986; 314:1676-86.

8. Nordin BE. Calcium and osteoporosis. Nutrition. 1997;13:664-86.

9. Sheikh MS, Santa Ana CA, Nicar MJ. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med. 1987;317:532-6.

10. Schinke T, Schilling AF, Baranowsky A. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med. 2009;15:674-82.

11. Yang YX, Lewis JD, Epstein S. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-53.

12. Chonan O, Takahashi R, Yasui H. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol. 1998; 44:473-81.

13. Chonan O, Takahashi R, Yasui H. Effect of L-lactic acid on the absorption of calcium in gastrectomized rats. J Nutr Sci Vitaminol. 1998; 44:869-75.

14. Goerss JB, Kim CH, Atkinson EJ. Risk of fractures in patients with pernicious anemia. J Bone Miner Res. 1992;7:573-9.

15. Graziani G, Como G, Badalamenti S. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10:1376-80.

16. Graziani G, Badalamenti S, Como G. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion Nephron. 2002;91:474-9.

17. Hardy P, Sechet A, Hottelart C. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosp-hatemia in patients on chronic hemodialisys. Artif Organs. 1998;22:569-73.

18. O'Connell MB, Madden DM, Murray AM. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778-81.

19. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104(Supl 2):S2-4.

20. Abrams SA. Using stable isotopes to asses mineral absorption and utilization by children. Am J Clin Nutr. 1999;70:955-64.

21. Hansen KE, Jones AN, Lindstrom MJ. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25: 2510-19.

22. Wright MJ, Sullivan RR, Gaffney-Stomberg E. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25:2205-11.

23. Esplugues JV. A pharmacological approach to gastric acid inhibition. Drugs. 2005;65(Supl 1):7-12.

24. Yuan FL, Li X, Lu WG. The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis. Mol Biol Rep. 2010;37: 3561-66.

25. Wu H, Xu G, Li YP. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res. 2009;24:871-85.

26. Geng W, Hill K, Zerwekh JE. Inhibition of osteoclast formation and function by bicarbonate: Role of soluble adenylyl cyclise. J Cell Physiol. 2009;220:332-40.

27. Mizunashi K, Furukawa Y, Katano K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53: 21-5.

28. Rzeszutek K, Sarraf F, Davies JE. Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth. J Craniofac Surg. 2003;14:301-7.

29. Sheraly AR, Lickorish D, Sarraf F. Use of gastrointestinal pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv. 2009;6:192-8.

30. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83.

31. Targownik LE, Lix LM, Metge CJ. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319-26.

32. Yu EW, Blackwell T, Ensrud KE. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251-9.

33. Corley DA, Kubo AI, Zhao W. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fracture among at-risk patients. Gastroenterology. 2010;139:93-101.

34. Gray SL, LaCroix AZ, Larson J. Proton pump inhibitors use, hip fracture and change in bone mineral density in postmenopausal women. Arch Int Med. 2010;170:765-71.

35. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol. 2009;104(Suppl 2):S21-6.

36. Grisso JA, Kelsey JL, O'Brien LA. Risk factors for hip fracture in man. Am J Epidemiol. 1997;145:786-93.

37. Schoofs MW, Van der Klift M, Hofman A. Thiazide diuretics and the risk of hip fracture. Ann Intern Med. 2003;139:476-82.

38. Van Staa TP, Leufkens HG, Abenhaim L. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.

39. Kanis JA, Borgstrom F, De Laet C. Assessment of fracture risk. Osteoporos Int. 2005;16:581-9.

40. Kaye JA, Jick H. Proton pump inhibitors use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951-9.

41. Bodmer M, Meier C, Kraenzlin ME. Proton pump inhibitors and fracture risk: true effector residual confounding? Drug Saf. 2010;33: 843-52.

42. Ye X, Liu H, Wu C. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:794-800.

43. Yu EW, Bauer SR, Bain PA. Proton pump inhibitors and risk of fractures: a metaanalysis of 11 international studies. Am J Med. 2011; 124:519-26.

44. Eom CS, Park SM, Myung SK. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9:257-67.

45. Ngamruengphong S, Leontiadis GI, Radhi S. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209-18.

46. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acidsuppressing medication. Bone. 2011;48:768-76.

47. Fraser LA, Leslie WD, Targownik LE. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24:1161-8.

48. Targownik LE, Lix LM, Leung S. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138:896-904.

49. Wainwright SA, Marshall LM, Ensrud KE. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787-893.

50. Kocher MS, Kasser JR. Osteopetrosis. Am J Orthop. 2003;32:222-8.

51. McGowan B, Bennett K, Barry M. Prescribing of antiosteoporotic therapies following the use of proton pump inhibitors in general practice. Pharmacoepidemiol Drug Saf. 2010;19:763-9.

52. Lee J, Youn K, Choi NK. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013 Jan 11.